The data gathered in the present study show that naturally cycling gonadal hormones influence fear extinction in that elevated gonadal hormone levels during the proestrus phase appear to facilitate extinction recall. This was further supported by 1) the fact that administration of exogenous estrogen and progesterone prior to extinction learning on Day 2 facilitated extinction recall tested on Day 3, and 2) the fact that blockade of estrogen and progesterone receptors prior to extinction learning impaired extinction recall. Furthermore, no differences were observed between male and female rats when not taking the cycle phase into consideration. However, after dividing the female rats based on the cycle phase, we observed marginal yet not significant sex differences during fear acquisition. Interestingly, during extinction recall, the fear recovery in female rats that underwent extinction learning during the metestrus phase was significantly higher when compared to fear recovery in males. Fear recovery in male rats and in females that underwent extinction learning during the proestrus phases were comparable. To our knowledge, this is the first report to indicate that in naturally cycling female rats, gonadal hormone variance during the estrous cycle modulates auditory fear extinction recall.
The objective of administering estrogen and progesterone was to determine which of these two hormones would modulate extinction learning and recall. Our data indicate that both estrogen and progesterone appear to enhance extinction recall. Notably, the combined estrogen and progesterone injections in the same animals seemed to have an additive effect, specifically during extinction learning. The decreased fear expression during extinction learning when elevated gonadal hormones are present is consistent with the reported anxiolytic effects of these hormones (
Lund et al. 2005;
Hiroi and Neumaier 2006;
Walf and Frye 2005). More importantly, the facilitated extinction consolidation induced by gonadal hormones is consistent with recent reports showing that estrogen administration facilitates extinction of contextually conditioned fear (
Chang et al. 2009) and memory formation in other tasks (
Leuner et al. 2004). We speculate that the facilitative effects of estrogen on fear extinction are mediated by the estrogen receptor beta (ER-beta), as several studies have shown that the anxiolytic effects of estrogen are mediated by the ER-beta (
Toufexis et al. 2007;
Lund et al. 2005;
Tomihara et al. 2009). This view is supported by a recent study showing that extinction of context conditioning was facilitated through the activation of ER-beta in the hippocampus (
Chang et al. 2009).
As for progesterone, its administration to ovarectomized rats facilitated contextual and cued fear conditioning, and enhanced cognitive performance in a variety of other behavioral tasks in mice (
Frye and Walf 2008). Moreover, progesterone is metabolized into allopregnanolone (
Engin and Treit 2007) which appears to have anxiolytic effects that are mediated via the amygdala, vmPFC, and hippocampus (
Akwa et al. 1999;
Engin and Treit 2007). In other tasks, progesterone facilitates extinction of cocaine self administration (
Jackson et al. 2006). We note that the progesterone receptor antagonist used in the present study, mifepristone, also blocks glucocorticoid receptors. Given that several studies have shown that glucocorticoids may be involved in fear extinction (
Yang et al. 2006;
Gourley et al. 2009), it is possible that the impaired extinction recall observed after mifepristone injections in the present study may be due to the blockade of the glucocorticoid receptors. Nonetheless, our other experiments involving natural hormone variations and exogenous progesterone administration show that progesterone is indeed playing a role in facilitating extinction recall.
The mechanisms by which estrogen and progesterone modulate associative learning are not entirely clear. High levels of gonadal hormone receptors are expressed in the vmPFC, hippocampus and amygdala (
Pilgrim and Hutchison 1994;
Ostlund et al. 2003); all of these brain regions have been implicated in fear extinction in both rodents and humans (
Quirk and Mueller 2008;
Milad et al. 2006a). These receptors are expressed on inhibitory interneurons in these brain regions, suggesting that activation of estrogen receptors may have a modulatory role on the output of the vmPFC, amygdala, and hippocampus (
Murphy et al. 1998;
Blurton-Jones and Tuszynski 2002). The interplay between gonadal hormones and neural activity has been most extensively studied in the hippocampus (
Shors et al. 2001). In this brain region, estrogen enhances synaptogenesis and long-term potentiation (LTP) (
McEwen 2002), increases the formation of dendritic spines (
Murphy et al. 1998;
Good et al. 1999), increases cell proliferation (
Tanapat et al. 2005), and increases neural excitability (
Foy et al. 1999;
Terasawa and Timiras 1968). GABA receptor agonists block the effects of estrogen on dendritic spines (
Segal and Murphy 2001). Thus, estrogen appears to reduce the inhibitory tone of GABAergic neurons. On the other hand, progesterone increases GABAergic inhibition and reduces dendritic spines in the hippocampus (
Segal and Murphy 2001;
Woolley and McEwen 1993). It remains unclear as to whether or not similar mechanisms of action of these hormones are also found in the amygdala and vmPFC, structures critical for fear acquisition and extinction.
Sex differences in the acquisition of cued and contextual fear conditioning have been demonstrated. The findings of these studies, however, are not entirely consistent, most likely due to differences in experimental protocol, dose, and duration of hormonal manipulations. Some studies have shown increased fear acquisition in male relative to female rats in a contextual fear conditioning paradigm (
Gupta et al. 2001;
Wiltgen et al. 2001). Others, however, reported no sex differences in contextual fear conditioning and reported enhanced fear acquisition to cued conditioning in female relative to male rats (
Wiltgen et al. 2005).
Maren et al.,(1994) observed sex differences during fear acquisition only during contextual fear and not during cued fear conditioning. Thus, our results are consistent with reports indicating lack of significant differences between male and female rats during cued fear conditioning. The lack of any sex differences remained even when considering the estrous cycle phase in females. Interestingly, sex differences emerged during extinction recall when taking the cycle phase into account. Male rats exhibited intact extinction recall that was comparable to female rats that underwent extinction learning while estrogen and progesterone levels were elevated. On the other hand, female rats that underwent extinction learning while estrogen and progestereon levels were low exhibited high freezing levels during this test. This is somewhat surprising as male rats might be expected to be at similar hormonal levels to metestrus rats.
The significantly elevated fear recovery in the Met_Ext group relative to male rats during extinction recall test may have clinical implications. Epidemiological data suggest that the prevalence of anxiety disorders is higher in women relative to men (
Pigott 2003;
Breslau et al. 1998;
Kinrys and Wygant 2005). Thus, the differences in prevalence and symptoms between women and men across the majority of anxiety disorders, point to brain-based differences in processing emotional stimuli in men and women (
Cahill 2003;
Goldstein et al. 2005b). The data gathered in the present study support this view and indicate that there may be an interaction between natural variance, as well as artificial manipulation of gonadal hormones, and the brain circuitry involved in fear inhibition (
Protopopescu et al. 2005). Such interaction should be further investigated, which could lead to hypotheses regarding how sex differences in anxiety disorders might be influenced by gonadal hormones. The influence of gonadal hormones on fear extinction in healthy humans has been shown in a preliminary study (
Milad et al. 2006a). Perhaps by concentrating exposure therapy at a particular phase of the cycle and/or administration of estrogen/progesterone in conjunction with exposure therapy, this line of research could help improve current treatments for anxiety disorders. It must be noted, however, that the experimental evidence presented herein is based on rodent’s data with an intact hormonal system. Speculations and translation of these findings into humans should be considered with caution. This is especially important given that it remains unclear how contraceptives (containing estrogen and progesterone) may influence the processes of fear learning and extinction in women.